Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort

Jochmann, Anja; Scherr, Andreas; Jochmann, Dirk Christian; Malka, David; Török, Salome Schafroth; Chhajed, Prashant N.; Tamm, Michael; Leüppi, Jörg D.

doi:10.4414/smw.2012.13567

Cited by 41 publications

(52 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, applicable standards are often forgotten during treatment [20,[31][32][33][34][35]. Furthermore, many patients do not adhere to medical recommendations concerning taking drugs or non-pharmacological treatment [19,34,36].…”

Section: Discussionmentioning

confidence: 99%

Factors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations

Wiśniewski

Porzezińska

Gruchała‐Niedoszytko

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. Systematic treatment of COPD decreases symptoms and reduces the frequency of exacerbations and hospitalisations because of the disease. It is estimated that only 50% of patients use prescribed drugs systematically. The aim of this study was to identify the factors which can influence adherence to treatment of the patients who were treated due to exacerbation of COPD. Material and Methods: A questionnaire probe was conducted on 49 patients hospitalised at the Regional Lung and Tuberculosis Hospital in Olsztyn, Poland due to COPD exacerbation. The assessed variables were: quality of life and adherence to treatment 30 days after discharge from hospital in relationship with demographic factors, social status, disease and hospitalisation course, and relief after systematic treatment. Results: Most of the patients assessed their health condition as poor and the disease as limiting their everyday social and occupational activity. 30 days after discharge from hospital the adherence rate to therapy was only 67%. There was an association between systematic treatment and the rate of exacerbations (p = 0.045) and hospitalisations (p = 0.005) but also clinical benefit after long-term treatment (p = 0.023). There were no associations between adherence to treatment and sex, place of residence, education or occupation. Conclusions: Lack of systematic treatment is the main risk factor for COPD exacerbations and hospitalisation rate. A subjective sense of relief after drugs is a factor improving patients’ compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations

Wiśniewski

Porzezińska

Gruchała‐Niedoszytko

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Although the impact of nonadherence to guidelines on efficacy outcomes is controversial [8], it increases healthcare costs [9] and, therefore, decreases cost-effectiveness. In addition, side-effects might be an issue for some treatments.…”

mentioning

confidence: 99%

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

et al. 2014

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) pharmacological treatment aims to reduce symptoms, represented mostly by dyspnoea and its impact on daily life, and future risk, i.e. lung function decline, mortality and exacerbations [1]. Inhaled therapies, including long-acting bronchodilators (LABD) and inhaled corticosteroids (ICS), are the main treatments recommended for COPD patients. LABD have been found not only to improve lung function, decrease dyspnoea, increase exercise tolerance and improve health status, but also to reduce the rate of exacerbations. In that respect, some studies suggested that long-acting antimuscarinic agents (LAMA) could be more effective than long-acting β 2 -agonists (LABA) [2]. In most countries, ICS are indicated only as part of fixed-dose combinations (FDC) with LABA and are used mostly to decrease the risk of exacerbations, which is associated with health status improvement [3]. Therefore, it appeared logical to restrict their use to patients at high risk of exacerbations. The long-term benefit of combining LAMA and FDC (triple therapy) is not strongly documented [4].

show abstract

“…For patients with asthma, some studies suggest that standardized guidelines can improve adherence to evidence-based treatment and reduce the financial burden of this disease (Jochmann et al, 2012). This situation may be similar for patients with COPD; however, there is an ongoing debate regarding the effectiveness of treatment protocols that conform to standardized guidelines.…”

Section: Introductionmentioning

confidence: 98%

“…Pharmaceutical guidelines for community health service centers in accordance with GOLD (2007 revision) (Jochmann et al, 2012) were as follows. i) Bronchodilators: Short-acting β 2 -adrenergic receptor stimulants were prescribed 4 times daily, or as required.…”

Section: Pharmaceutical Guidelinesmentioning

confidence: 99%

Impact of adherence to GOLD guidelines on 6-minute walk distance, MRC dyspnea scale score, lung function decline, quality of life, and quality-adjusted life years in a Shanghai suburb

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. We performed a 1-year cluster-randomized field trial to assess the effect of standardized management of chronic obstructive Y.Q. Jiang et al. 8862©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 8861-8870 (2015) pulmonary disease (COPD) on lung function and quality of life (QOL) measures in patients in China. We used the Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines and assessed indexes including pulmonary function, QOL, quality-adjusted life years (QALY), Medical Research Council (MRC) dyspnea scale, 6-min walk distance (6-MWD), number of emergency visits, and frequency of hospitalization. Of a total of 711 patients with chronic cough and asthma, 132 were diagnosed as having COPD and 102 participated in this study [intervention group (N = 47); control group (N = 55)]. We found that adherence to GOLD guidelines had a perceivable impact on 6-MWD, MRC dyspnea scale score, and QOL. The average QALY increased by 1.42/person/year in the intervention group, but declined by 0.95/person/year in the control group. We conclude that standardized management improves disease severity, QOL, and QALY in COPD patients when treatment protocols adhere to GOLD guidelines.

show abstract

Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort

Abstract: While there was no improvement in adherence to GOLD guidelines, disease severity was not affected detrimentally, suggesting that guideline adherence does not seem to impact symptom prevalence, exacerbation rate or lung function decline after one year of follow up.

Cited by 41 publications

References 26 publications

Factors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations

Factors Influencing Adherence to Treatment in COPD Patients and Its Relationship with Disease Exacerbations

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

Impact of adherence to GOLD guidelines on 6-minute walk distance, MRC dyspnea scale score, lung function decline, quality of life, and quality-adjusted life years in a Shanghai suburb

Contact Info

Product

Resources

About